How to appeal a Cigna rare disease — ert, substrate reduction, gene therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for rare disease — ert, substrate reduction, gene therapy

Cited policy: Cigna coverage policy (ERT) + disease-specific (coverage policy Galafold, Brineura)

Confirmed dx; specialist; appropriate phenotype (e.g., Galafold only for amenable GLA mutations on FDA-approved list).

How Cigna denies rare disease — ert, substrate reduction, gene therapy — and how to counter it

Where Cigna pushes back: 1) 'Galafold mutation not on amenable list'; 2) 'Brineura not medically necessary outside CLN2 motor-language score window'; 3) Off-label denial (e.g., miglustat for NPC).

Counter-arguments that hold up: For Galafold: cite Amicus's HEK assay evidence + FDA-amenable mutation table (list expands with new evidence). For Brineura: cite Schulz NEJM 2018 — preserves motor-language function; irreversible CNS decline without treatment. For off-label miglustat in NPC: cite 42 USC §1395x(t)(2) and DRUGDEX Level IIa support; EMA approval is FDA-recognized indication of efficacy.

What Cigna typically denies for rare disease — ert, substrate reduction, gene therapy

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For rare disease — ert, substrate reduction, gene therapy, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the rare disease — ert, substrate reduction, gene therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pompe ERT
• Fabry ERT
• Galafold (Fabry SRT)
• Gaucher ERT
• Gaucher SRT
• MPS I ERT

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.